Drug
Ceritinib clinical trials
Also written LDK378 and Zykadia.
- studies test it
- 39
- open now
- 2
- in phase 3
- 3
- first study started
- 2011
Keep track of what changes. Save the ceritinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
38 studies that test it; most in 2015 (14); 1 more planned to start later
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2012 | 3 |
| 2013 | 5 |
| 2014 | 3 |
| 2015 | 14 |
| 2016 | 4 |
| 2017 | 1 |
| 2018 | 3 |
| 2019 | 3 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 16
- Phase 2
- 20
- Phase 3
- 3
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 18
Novartis Pharmaceuticals (20) · H. Lee Moffitt Cancer Center and Research Institute (2) · Yonsei University (2) · University of Texas Southwestern Medical Center (2) · University of California, San Francisco (2) · M.D. Anderson Cancer Center (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · St. Joseph's Hospital and Medical Center, Phoenix (1)
Often tested with
Tested in the same studies.
Capmatinib (3) · Trametinib (3) · Ribociclib (2) · Brigatinib (2) · Nivolumab (1) · Everolimus (1) · Docetaxel (1) · Nilotinib (1)
Studies
Open first, then newest update. How each study uses ceritinib is read from its arms, and is right about nine times in ten.
Testing it · 39
- Ceritinib Treatment for Recurrent MeningiomasNot yet recruitingPhase 2Kevin PetreccaNCT07893197Written as Ceritinib
- Using Tumor Models to Determine TreatmentsRecruitingPhase 2University Health Network, TorontoNCT06813079Written as Ceritinib
- Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung CancerActive, not recruitingPhase 1Novartis PharmaceuticalsNCT02393625Written as Ceritinib (LDK378)
- Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored StudyActive, not recruitingPhase 4Novartis PharmaceuticalsNCT02584933Written as ceritinib
- An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 RearrangementCompletedPhase 2Yonsei UniversityNCT01964157Written as LDK378
- Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung CancerActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT02321501Written as Ceritinib
- Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLCActive, not recruitingPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT03611738Written as Ceritinib
- Molecular Profiling of Advanced Soft-tissue SarcomasCompletedPhase 3Institut National de la Santé Et de la Recherche Médicale, FranceNCT03784014Written as Ceritinib
- Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerTerminatedPhase 2National Cancer Institute (NCI)NCT03737994Written as Ceritinib
- Next Generation Personalized Neuroblastoma TherapyTerminatedPhase 1Yael P MosseNCT02780128Written as Ceritinib
- Study of Trametinib + Ceritinib in Patients With Unresectable MelanomaCompletedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT03501368Written as Ceritinib
- LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and CrizotinibCompletedPhase 3Novartis PharmaceuticalsNCT01828112Written as Ceritinib
- LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung CancerCompletedPhase 3Novartis PharmaceuticalsNCT01828099Written as Ceritinib
- Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung AdenocarcinomaTerminatedPhase 2University of Texas Southwestern Medical CenterNCT02513667Written as Ceritinib
- Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)TerminatedPhase 1University of California, San FranciscoNCT03087448Written as Ceritinib
- Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)CompletedPhase 1Novartis PharmaceuticalsNCT02299505Written as ceritinib
- Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)TerminatedPhase 2Novartis PharmaceuticalsNCT02186821Written as Ceritinib
- LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.CompletedPhase 2Novartis PharmaceuticalsNCT02450903Written as LDK378
- A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced TumorsCompletedPhase 1Novartis PharmaceuticalsNCT02422589Written as ceritinib
- Effect of Hepatic Impairment on LDK378 PharmacokineticsCompletedPhase 1Novartis PharmaceuticalsNCT01950481Written as LDK378
See all 39 studies that test ceritinib →
Given in every arm · 2 — ceritinib is usual care beside what is tested
- Pediatric Precision Laboratory Advanced Neuroblastoma TherapyRecruitingPhase 2Giselle ShollerNCT02559778Written as Ceritinib
- Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic CancerCompletedPhase 1Roswell Park Cancer InstituteNCT02227940Written as Ceritinib
Codes
What other systems call ceritinib · ClinicalTrials.gg INT006447
- MeSH (NLM) C586847ceritinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) K418KG2GETCERITINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1535457Confirmed FDA, Wikidata
- Wikidata Q21011233ceritinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C115112CeritinibOne source FDA
- DrugBank DB09063One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C586847 | ceritinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | K418KG2GET | CERITINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1535457 | — | Confirmed FDA, Wikidata |
| Wikidata | Q21011233 | ceritinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C115112 | Ceritinib | One source FDA |
| DrugBank | DB09063 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.